Compound | Retention Time (min) | MRM Transition | Initial Condition | Final Condition | Column |
---|---|---|---|---|---|
Caffeine | 1.03 | 195.2:138.1 | 70% A/30% B | 70% A/30% B | Luna Phenyl Hexyl 5 × 4.6, 5 μa |
CP-141938 | 1.40 | 404.3:160.2 | 25% A/75% B | 25% A/75% B | Synergi Polar RP 5 × 4.6, 4 μa |
Fluoxetine | 2.80 | 310.1:148.1 | 90% A/10% B | 10% A/90% B | Primesphere C18 3 × 2, 5 μa |
Midazolam | 1.48 | 326.2:291.1 | 25% A/75% B | 25% A/75% B | Synergi Polar RP 5 × 4.6 4 μa |
NFPS | 3.66 | 394.0:102.1 | 90% A/10% B | 10% A/90% B | Primesphere C18 3 × 2, 5 μa |
Propranolol | 3.48 | 260.1:116.2 | 90% A/10% B | 10% A/90% B | Primesphere C18 3 × 2, 5 μa |
Quinidine | 2.83 | 325.3:307.4 | 90% A/10% B | 10% A/90% B | Ace C18 5 × 4.6, 5 μb |
Theobromine | 1.10 | 181.1:138.2 | 25% A/50% B/25% C | 25% A/50% B/25% C | Ace C18 5 × 4.6, 5 μb |
Theophylline | 1.25 | 181.1:124.1 | 25% A/75% B | 25% A/7/5% B | Ace C18 5 × 4.6, 5 μb |
Thiopental | 1.16 | 241.4:101.0 | 25% A/75% B | 25% A/75% B | Synergi Polar RP 5 × 4.6, 4 μa |
Sulpiride | 1.61 | 342.0:112.1 | 25% A/75% B | 25% A/75% B | Synergi Polar RP 5 × 4.6, 4 μa |
Zolpidem | 1.46 | 308.2:235.2 | 25% A/75% B | 25% A/75% B | Synergi Polar RP 5 × 4.6, 4 μa |
9-OH Risperidone | 1.15 | 427.2:207.2 | 25% A/75% B | 25% A/75% B | Synergi Polar RP 50 × 4.6, 4 μa |